Psoriatic Arthritis News

Patients who received rheumatology care from nurse practitioners or physician assistants rated their overall experience similarly to those who saw a rheumatologist, according to survey data published in Arthritis Care & Research.

Routine care for inflammatory arthritis should include self-management strategies that feature problem-solving, goal-setting and, if possible, cognitive behavioral therapy, according to new EULAR recommendations.

Air pollution is a predictor of poor response to biological treatment in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, according to a poster session at the EULAR 2021 Congress.

Secukinumab yielded a significantly longer time to flare than placebo in pediatric patients with enthesitis-related arthritis and juvenile psoriatic arthritis, according to findings presented at the EULAR 2021 Congress.

Guselkumab 100 mg administered every 8 weeks results in “significantly higher” ACR20 response rates vs. placebo in patients with psoriatic arthritis who had an inadequate response to TNF inhibitors, according to data presented at the EULAR 2021 Virtual Congress.

Although a range of biologic options are available to clinicians treating psoriatic arthritis, it crucial to know which disease domains are involved as this will “dictate treatment,” according to a presenter at the Biologic Therapies Summit.

Fecal microbiota transplantation is safe in patients with psoriatic arthritis, according to data from the first preliminary, randomized trial of the procedure in immune-mediated arthritis.

Findings from the Live Yes! INSIGHTS survey from the Arthritis Foundation showed that out of some 40,000 patient responses, 100% reported experiencing some kind of pain within the last 7 days.

The U.S. Supreme Court has denied a petition from Novartis’ Sandoz to review an earlier U.S. appeals court ruling in favor of Amgen’s etanercept against etanercept-szzs, effectively blocking the biosimilar from entering the U.S. market.

Proactive therapeutic drug monitoring vs. standard therapy did not significantly improve clinical remission rates over 30 weeks in patients with immune-mediated inflammatory diseases initiating Remicade therapy, according to study results.